Derik De Bruin
Stock Analyst at B of A Securities
(3.70)
# 709
Out of 5,172 analysts
223
Total ratings
65.77%
Success rate
15.78%
Average return
Main Sectors:
Stocks Rated by Derik De Bruin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| WAT Waters | Maintains: Neutral | $410 → $350 | $298.99 | +17.06% | 15 | Feb 10, 2026 | |
| BRKR Bruker | Maintains: Buy | $43 → $60 | $33.35 | +79.91% | 14 | Dec 15, 2025 | |
| A Agilent Technologies | Maintains: Neutral | $150 → $165 | $111.30 | +48.25% | 34 | Nov 25, 2025 | |
| MTD Mettler-Toledo International | Maintains: Neutral | $1,260 → $1,390 | $1,204.48 | +15.40% | 11 | Sep 22, 2025 | |
| DHR Danaher | Maintains: Buy | $230 → $220 | $189.35 | +16.19% | 5 | Sep 22, 2025 | |
| PAHC Phibro Animal Health | Maintains: Underperform | $19 → $27 | $50.76 | -46.81% | 5 | Aug 29, 2025 | |
| RVTY Revvity | Maintains: Buy | $116 → $110 | $85.94 | +28.00% | 3 | Jun 26, 2025 | |
| TXG 10x Genomics | Maintains: Neutral | $12 → $13 | $18.39 | -29.31% | 9 | Jun 26, 2025 | |
| QGEN Qiagen | Maintains: Buy | $48 → $50 | $39.93 | +26.42% | 6 | Jun 26, 2025 | |
| MYGN Myriad Genetics | Maintains: Underperform | $13 → $11 | $4.58 | +140.17% | 13 | Mar 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $72 → $65 | $104.91 | -38.04% | 7 | Feb 20, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $19 → $16 | $7.96 | +101.01% | 5 | Feb 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $675 → $660 | $474.39 | +39.13% | 18 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $255 → $235 | $166.07 | +41.51% | 3 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $220 → $210 | $153.60 | +36.72% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $350 → $355 | $237.03 | +49.77% | 7 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $24 → $26 | $14.60 | +78.08% | 4 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $262 → $271 | $263.00 | +3.04% | 8 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $179 → $182 | $195.26 | -6.79% | 5 | Dec 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $26 → $21 | $9.53 | +120.36% | 5 | Aug 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $38 → $32 | $12.02 | +166.22% | 1 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $140 → $100 | $124.33 | -19.57% | 11 | Dec 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $94 → $86 | $75.41 | +14.04% | 11 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $13 | $2.43 | +434.98% | 1 | Jun 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 → $6.5 | $1.68 | +286.90% | 1 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $265 → $260 | $99.70 | +160.78% | 1 | Nov 9, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $240 → $120 | $6.71 | +1,688.38% | 3 | May 18, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $111 → $120 | $115.67 | +3.74% | 2 | Jul 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Underperform | $10 → $9 | $1.93 | +366.32% | 7 | May 8, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $275 → $235 | $577.26 | -59.29% | 3 | Nov 2, 2018 |
Waters
Feb 10, 2026
Maintains: Neutral
Price Target: $410 → $350
Current: $298.99
Upside: +17.06%
Bruker
Dec 15, 2025
Maintains: Buy
Price Target: $43 → $60
Current: $33.35
Upside: +79.91%
Agilent Technologies
Nov 25, 2025
Maintains: Neutral
Price Target: $150 → $165
Current: $111.30
Upside: +48.25%
Mettler-Toledo International
Sep 22, 2025
Maintains: Neutral
Price Target: $1,260 → $1,390
Current: $1,204.48
Upside: +15.40%
Danaher
Sep 22, 2025
Maintains: Buy
Price Target: $230 → $220
Current: $189.35
Upside: +16.19%
Phibro Animal Health
Aug 29, 2025
Maintains: Underperform
Price Target: $19 → $27
Current: $50.76
Upside: -46.81%
Revvity
Jun 26, 2025
Maintains: Buy
Price Target: $116 → $110
Current: $85.94
Upside: +28.00%
10x Genomics
Jun 26, 2025
Maintains: Neutral
Price Target: $12 → $13
Current: $18.39
Upside: -29.31%
Qiagen
Jun 26, 2025
Maintains: Buy
Price Target: $48 → $50
Current: $39.93
Upside: +26.42%
Myriad Genetics
Mar 3, 2025
Maintains: Underperform
Price Target: $13 → $11
Current: $4.58
Upside: +140.17%
Feb 20, 2025
Maintains: Buy
Price Target: $72 → $65
Current: $104.91
Upside: -38.04%
Feb 19, 2025
Maintains: Neutral
Price Target: $19 → $16
Current: $7.96
Upside: +101.01%
Dec 13, 2024
Maintains: Buy
Price Target: $675 → $660
Current: $474.39
Upside: +39.13%
Dec 13, 2024
Maintains: Buy
Price Target: $255 → $235
Current: $166.07
Upside: +41.51%
Dec 13, 2024
Maintains: Neutral
Price Target: $220 → $210
Current: $153.60
Upside: +36.72%
Dec 13, 2024
Maintains: Buy
Price Target: $350 → $355
Current: $237.03
Upside: +49.77%
Dec 13, 2024
Maintains: Buy
Price Target: $24 → $26
Current: $14.60
Upside: +78.08%
Dec 13, 2024
Maintains: Buy
Price Target: $262 → $271
Current: $263.00
Upside: +3.04%
Dec 13, 2024
Maintains: Buy
Price Target: $179 → $182
Current: $195.26
Upside: -6.79%
Aug 13, 2024
Maintains: Underperform
Price Target: $26 → $21
Current: $9.53
Upside: +120.36%
Feb 29, 2024
Maintains: Neutral
Price Target: $38 → $32
Current: $12.02
Upside: +166.22%
Dec 12, 2023
Downgrades: Underperform
Price Target: $140 → $100
Current: $124.33
Upside: -19.57%
Aug 1, 2023
Maintains: Neutral
Price Target: $94 → $86
Current: $75.41
Upside: +14.04%
Jun 16, 2023
Downgrades: Neutral
Price Target: $13
Current: $2.43
Upside: +434.98%
Jan 4, 2023
Downgrades: Underperform
Price Target: $9 → $6.5
Current: $1.68
Upside: +286.90%
Nov 9, 2022
Upgrades: Buy
Price Target: $265 → $260
Current: $99.70
Upside: +160.78%
May 18, 2022
Downgrades: Underperform
Price Target: $240 → $120
Current: $6.71
Upside: +1,688.38%
Jul 1, 2019
Downgrades: Neutral
Price Target: $111 → $120
Current: $115.67
Upside: +3.74%
May 8, 2019
Reiterates: Underperform
Price Target: $10 → $9
Current: $1.93
Upside: +366.32%
Nov 2, 2018
Maintains: Buy
Price Target: $275 → $235
Current: $577.26
Upside: -59.29%